While some antidepressants may affect the metabolism and efficacy of tamoxifen, many antidepressants can be used safely in this population. The post Clinical Update 2024: Recommendations on the Use of Antidepressants in Women Taking Tamoxifen appeared first on MGH Center for Women's Mental Health ..read more

As of October 2023, the Neurosteroid Intervention for Menopausal and Perimenopausal Depression is no longer recruiting participants. Over the last few years we have heard a great deal about neurosteroids, also known as neuroactive steroids. This class of compounds are steroid hormones produced in the brain and endocrine tissues which can modulate neurotransmission. Animal studies [...] The post Recruiting for Research Study: Pregnenolone Neurosteroid for Menopausal Depression appeared first on MGH Center for Women's Mental Health ..read more

Menopause is a period of increased risk for women with schizophrenia spectrum disorders, and women are at higher risk for relapse than their age-matched male counterparts. The post Menopause Increases Risk of Relapse in Women with Schizophrenia appeared first on MGH Center for Women's Mental Health ..read more

While many peri- and post-menopausal women request bioidentical hormones, there is no data to suggest that bioidential hormones are safer or more effective than FDA-approved hormone replacement therapies. The post Essential Reads: What You Need to Know About Bioidentical Hormone Therapy for Menopausal Symptoms appeared first on MGH Center for Women's Mental Health ..read more

The FDA accepted a New Drug Application for fezolinetant, a novel, nonhormonal selective neurokinin-3 receptor (NK3R) antagonist for the treatment of menopause-related vasomotor symptoms. The post FDA Accepts New Drug Application for Fezolinetant, A Novel Nonhormonal Treatment for Vasomotor Symptoms appeared first on MGH Center for Women's Mental Health ..read more